[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612563":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":11,"centralContacts":31,"locations":37,"responsibleParty":60,"collaborators":11,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":11,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":11,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Innovent Biologics (Suzhou) Co. Ltd.","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR",null,[13],"Drug: Placebo",{"label":15,"type":16,"description":11,"interventionNames":17},"IBI362-dose2","EXPERIMENTAL",[18],"Drug: IBI362",{"label":20,"type":16,"description":11,"interventionNames":21},"IBI362-dose1",[18],[23,27],{"type":24,"name":9,"description":25,"armGroupLabels":26,"otherNames":11},"DRUG","Placebo SA.QW",[9],{"type":24,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"IBI362","IBI362 SA.QW",[20,15],[32],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Xiaoyan li","CONTACT","18756032014","xiaoyan.li@innoventbio.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"The Children's Hospital, Zhejiang University School of Medicine","RECRUITING","Hangzhou","Zhejiang","310052","China","CN",{"type":47,"coordinates":48},"Point",[49,50],120.16142,30.29365,{"lat":50,"lon":49},[53,57],{"name":54,"role":34,"phone":55,"phoneExt":11,"email":56},"Junfen Fu","13777457849","fjf68@zju.edu.cn",{"name":58,"role":59,"phone":11,"phoneExt":11,"email":11},"Junfen Fu, M.D","PRINCIPAL_INVESTIGATOR",{"type":61,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100612563","phase-3-a-study-of-ibi362-in-chinese-adolescents-with-obesity-or-overweight-100612563",false,"NCT07255209","A Study of IBI362 in Chinese Adolescents With Obesity or Overweight","A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）","Inclusion Criteria:\n\nParticipants must meet all of the following inclusion criteria to be enrolled:\n\nKey Inclusion Criteria：\n\n1. Male or female participants aged ≥12 years and \\\u003C18 years at the time of signing the informed consent\u002Fassent form.\n2. BMI at screening meeting the obesity criteria defined by \"WS\u002FT 586-2018 Screening for Overweight and Obesity in School-Age Children and Adolescents\" or meeting overweight criteria plus at least one weight-related comorbidity: prediabetes, type 2 diabetes, hypertension, dyslipidemia, fatty liver disease, or obstructive sleep apnea syndrome.\n3. Weight change \\\u003C5 kg after ≥12 weeks of diet and exercise alone before screening (per self\u002Fparental report).\n\nExclusion Criteria:\n\nKey Exclusion Criteria：\n\n1. Prior diagnosis of type 1 diabetes.\n2. Pre-pubertal participants (Tanner Stage I).\n3. History of (or planned) bariatric surgery (except liposuction\u002Fabdominoplasty or acupuncture for weight loss performed \\>1 year before screening).","ALL","12 Years","18 Years",{"count":73,"type":74},180,"ESTIMATED","INTERVENTIONAL",[77],"PHASE3","The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and \\\u003C18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.",[80],"Adolescents With Obesity or Overweight With Weight-Related Comorbidities","2026-01-07",{"date":83,"type":84},"2026-01-08","ACTUAL",{"date":86,"type":84},"2025-12-29",{"date":88,"type":74},"2028-10-31",{"name":5,"class":6},1]